TMCnet News
Medidata Partners With CTI for Remote Source Review of Clinical Trials in Response to COVID-19Medidata, the global leader in creating end-to-end solutions to support the entire clinical trial process, and a Dassault Systèmes company, announced that CTI (News - Alert) Clinical Trial and Consulting Services, a leading contract research organization, will use Medidata's Remote Source Review to power remote monitoring and document review for multiple global studies, including several COVID-19 projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200708005231/en/ The COVID-19 pandemic has placed an unprecedented strain on drug and vaccine research because of limitations on travel and access to clinical research sites. (For more information, see COVID-19 and Clinical Trials: The Medidata Perspective.) One way Medidata is supporting the continuation of trials during these times is by aligning its imaging workflow solution to rapidly, securely, and remotely assist researchers in critical document acquisition and source document review. "Medidata is committed to developing and deploying the technology necessary to maintain the momentum of discovery," said Glen de Vries, co-founder and co-CEO, Medidata. "We're pleased to be partnering with CTI on these important, promising trials for patients with rare and infectious diseases, and cancer. It's more important than ever that we think and plan our way around the obstacles COVID-19 has put in the path of medical progress." Medidata Remote Source (News - Alert) Review, a quick-to-implement technology built on Medidata's industry-leading Rave Imaging system, is already deployed in more than 15,000 clinical sites. This 21 CFR Part 11 compliant solution is especially valuable when studies have critical timelines, and there are no secure options to collect, review, de-identify, and redact Personally Identifiable Information (PII). Less secure, antiquated tools such as fax, email, video, and file sharing software solutions place timelines and data integrity at risk. Remote Source Review also helps improve clinical research associate (CRA) productivity by decreasing travel time and costs. "Standardizing our trials with Medidata technology and enhancing our remot monitoring capabilities are critically important during the pandemic," said Timothy Schroeder, Chief Executive Officer and Founder, CTI. "Their scalable solutions will also take us beyond COVID-19. The future lies in minimizing disruptions to research, accelerating the move toward more virtual trial management, ensuring data collection and integrity, and managing source documents remotely, as needed." Medidata is a wholly owned subsidiary of Dassault Systèmes (News - Alert), which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.
About Medidata
Medidata and Medidata Rave are registered trademarks of Medidata Solutions, Inc., a wholly owned subsidiary of Dassault Systèmes.
About Dassault Systèmes
3DEXPERIENCE, the Compass (News - Alert) icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, EXALEAD, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French "société européenne" (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.
About CTI Clinical Trial and Consulting Services
View source version on businesswire.com: https://www.businesswire.com/news/home/20200708005231/en/ |